Raptor and Nuron secure new funding through non-dilutive HC Royalty deals
This article was originally published in Scrip
Executive Summary
HealthCare Royalty Partners (HC Royalty) has committed $130 million to finance development and commercialization of products from Raptor Pharmaceutical and Nuron Biotech tied to royalties from future product sales.